Yeah, but I see a few steps forward, and a few back as they raise capital from the old warrants; and then a few forward again. The company will attract new buyers, very good chance of clinical success provided they can keep toxicities down. So far they have done very good in that regards. :)
News 
Market Data 
Discover 
